Oral drugs for antiplatelet aggregation include aspirin enteric-coated tablets, clopidogrel bisulfate tablets, dipyridamole, and calcium hydroxybenzenesulfonate capsules. 1. Aspirin enteric-coated tablets: small doses of aspirin enteric-coated tablets can inhibit the synthesis of platelets and endothelial thromboxane A2 and inhibit platelet aggregation. However, this drug may cause nausea, epigastric discomfort and other adverse reactions, active ulcer disease or other causes of gastrointestinal bleeding patients are prohibited. 2. Clopidogrel Hydrogen Sulfate Tablets: Inhibit platelet activation induced by adenosine diphosphate by blocking platelet receptors, thus reducing platelets. However, this drug may cause abdominal pain, bleeding and other adverse reactions, if the patient has a recent bleeding tendency, such as peptic ulcer or craniocerebral trauma, allergic to this drug, pregnant women and breastfeeding and so on are prohibited. 3. Dipyridamole: Dipyridamole can inhibit phosphodiesterase activity and mildly inhibit platelet cyclooxygenase, thus inhibiting platelet aggregation. Adverse reactions such as dizziness, headache and vomiting may occur with the use of this drug. It is contraindicated for those who are allergic to dipyridamole, pregnant women and lactating women. 4. Calcium hydroxybenzenesulfonate capsule: Calcium hydroxybenzenesulfonate capsule can inhibit platelet aggregation by regulating the physiological function of microvascular wall, reducing resistance, lowering plasma viscosity and platelet aggregation. However, adverse reactions such as nausea and heartburn may occur with this drug. It is contraindicated for those who are allergic to the product and any components of the preparation, pregnant and lactating women. When patients have the need for medication, they should use it rationally under the guidance of specialized doctors.